G&A at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's G&A?
- Viking Therapeutics (VKTX) reported G&A of $13.98M in Q1 2026.
- How has Viking Therapeutics's G&A changed year-over-year?
- Viking Therapeutics's G&A decreased by 0.7% year-over-year, from $14.08M to $13.98M.
- What is the long-term trend for Viking Therapeutics's G&A?
- Over 4 years (2021 to 2025), Viking Therapeutics's G&A has grown at a 45.8% compound annual growth rate (CAGR), from $10.7M to $48.39M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.